Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients

Current Gastroenterology Reports

Volumn 13, Issue 4, 2011, Pages 344-350

  Raines, Daniel L ^a   Lopez, Fred A ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired Immunodeficiency Syndrome (AIDS); Antibiotic associated Colitis (AAC), Pseudomembranous Colitis; Clostridium difficile; Clostridium difficile Infection (CDI); Clostridium difficile associated Diarrhea (CDAD); Human Immunodeficiency Virus (HIV)

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BACTERIAL ANTIGEN; CISPLATIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; METRONIDAZOLE; PACLITAXEL; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CYTOTOXICITY TEST; ENVIRONMENTAL SANITATION; ENZYME IMMUNOASSAY; FECES BIOTHERAPY; FECES CULTURE; FUNGEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; LEUKOCYTE COUNT; MORBIDITY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; THERAPY;

CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HIV; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 80051599837     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-011-0196-6     Document Type: Review

References (50)

1. IC Hall E O'Toole 1935 Intestinal flora in new-born infants with a description of a new pathogenic anaerobe: Bacillus difficilis Am J Dis Child 48 390 402
2. JG Bartlett TE Chang M Gurwith 1978 Antibiotic-associated pseudomembranous colitis due to toxin-producing Clostridia N Engl J Med 298 10 531 4 625309 10.1056/NEJM197803092981003 1:STN:280:DyaE1c7htlyqug%3D%3D (Pubitemid 8295586)
3. R Viscidi S Willey JG Bartlett 1981 Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations Gastroenterology 81 1 5 9 7239125 1:STN:280:DyaL3M3htlelug%3D%3D (Pubitemid 11078473)
4. EJ Kuijper B Coignard P Tull 2006 Emergence of Clostridium difficile-associated disease in North America and Europe Clin Microbiol Infect 12 S6 2 18 16965399 10.1111/j.1469-0691.2006.01580.x 1:CAS:528: DC%2BD28XhtFyhsLbN (Pubitemid 44362038)
5. CT Clabots S Johnson MM Olson, et al. 1992 Acquisition of Clostridium difficile by hospitalized patients J Infect Dis 166 561 7 1323621 10.1093/infdis/166.3.561 1:STN:280:DyaK38zmsVertw%3D%3D
6. L Kyne MB Hamel R Polavaram CP Kelly 2002 Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile Clin Infect Dis 34 346 53 11774082 10.1086/338260 (Pubitemid 34062235)
7. TH Sanchez JT Brooks PS Sullivan, et al. 2005 Bacterial diarrhea in persons with HIV infection, United States, 1992-2002 Clin Infect Dis 41 1621 7 16267735 10.1086/498027 (Pubitemid 41691601)
8. SH Cohen DN Gerding S Johnson, et al. 2010 Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infect Control Hosp Epidemiol 31 5 431 55 20307191 10.1086/651706 This publication describes the most recent consensus guidelines for the diagnosis, treatment, and prevention of C. difficile infection from the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
9. DE Voth JD Ballard 2005 Clostridium difficile toxins: mechanism of action and role in disease Clin Microbiol Rev 18 2 247 63 15831824 10.1128/CMR.18.2.247-263.2005 1:CAS:528:DC%2BD2MXksVymtLY%3D (Pubitemid 40548293)
10. VG Loo L Poirier MA Miller, et al. 2005 A predominately clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality N Engl J Med 353 2442 9 16322602 10.1056/NEJMoa051639 1:CAS:528:DC%2BD2MXhtlShurvK (Pubitemid 41770165)
11. S Sivapalasingham MJ Blaser 2005 Bacterial diarrhea in HIV-infected patients. Why Clostridium difficile, and why now? Clin Infect Dis 41 1628 30 10.1086/498037 (Pubitemid 41691602)
12. LV McFarland ME Mulligan RY Kwok WE Stamm 1989 Nosocomial acquisition of Clostridium difficile infection N Engl J Med 320 204 10 2911306 10.1056/NEJM198901263200402 1:STN:280:DyaL1M%2FpslWhtw%3D%3D (Pubitemid 19034145)
13. R Viscidi BE Laughon R Yolken, et al. 1983 Serum antibody responses to toxins A and B of Clostridium difficile J Infect Dis 148 93 100 6886489 10.1093/infdis/148.1.93 1:STN:280:DyaL3s3pt1ynsQ%3D%3D (Pubitemid 13039317)
14. L Kyne M Warny A Qamar CP Kelly 2000 Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A N Eng J Med 342 390 7 10.1056/NEJM200002103420604 1:STN:280:DC%2BD3c7hs12mtg%3D%3D (Pubitemid 30084537)
15. L Kyne M Warny A Qamar CP Kelly 2001 Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea Lancet 357 189 93 11213096 10.1016/S0140-6736(00)03592-3 1:CAS:528:DC%2BD3MXptVyruw%3D%3D (Pubitemid 32108091)
16. BA Leav B Blair M Leney, et al. 2010 Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI) Vaccine 28 965 9 19941990 10.1016/j.vaccine.2009.10.144 1:CAS:528: DC%2BC3cXntlSltg%3D%3D This recent study demonstrates that antibodies generated against toxin B may be as important as or more important than antibodies against toxin A in the immune response to C. difficile infection
17. A DeMilito A Nilsson K Titanji, et al. 2004 Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection Blood 103 2180 6 10.1182/blood-2003-07-2375 1:CAS:528: DC%2BD2cXitlequ7w%3D (Pubitemid 38326236)
18. L Hunziker M Recher AJ Macpherson, et al. 2003 Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections Nat Immunol 4 343 9 12627229 10.1038/ni911 1:CAS:528:DC%2BD3sXitlyqs7g%3D (Pubitemid 36432316)
19. LC McDonald M Owings DB Jernigan 2006 Clostridium difficile infection in patients discharged from U.S. short-stay hospitals, 1996-2003 Emerg Infect Dis 12 409 15 16704777
20. LV McFarland GW Elmer WE Stamm ME Mulligan 1991 Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile in a cohort study of hospitalized patients Infect Immun 59 2456 62 2050409 1:STN:280:DyaK3M3mslKhtA%3D%3D
21. SH Cheng JJ Lu TG Young, et al. 1997 Clostridium difficile-associated disease: comparison of symptomatic infection versus carriage rate on the basis of risk factors, toxin production, and genotyping results Clin Infect Dis 25 157 8 9243055 10.1086/516891 1:STN:280:DyaK2szos12qsA%3D%3D
22. T Akerlund B Svenungsson A Lagergren LG Burman 2006 Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates J Clin Microbiol 44 2 353 8 16455883 10.1128/JCM.44.2.353-358.2006 (Pubitemid 43222222)
23. SL Stubbs JS Brazier GL O'Neill BI Duerden 1999 PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes J Clin Microbiol 37 461 3 9889244 1:CAS:528:DyaK1MXht1Wqsrw%3D (Pubitemid 29056430)
24. J Pepin L Valiquette ME Alary, et al. 2004 Clostridium difficile-associated diarrhea in a region of Quebex from 1991 to 2003 Can Med Assoc J 171 466 72 10.1503/cmaj.1041104 (Pubitemid 39179608)
25. WN Fawley P Parnell J Verity, et al. 2005 Molecular epidemiology of endemic Clostridium difficile infection and the significance of subtypes of the United Kingdom epidemic strain (PCR Ribotype 1) J Clin Microbiol 43 2685 96 15956384 10.1128/JCM.43.6.2685-2696.2005 1:CAS:528:DC%2BD2MXlvFOiu70%3D (Pubitemid 40827940)
26. TD Wilkins DM Lyerly 2003 Clostridium difficile testing: after 20 years, still challenging J Clin Microbiol 41 2 531 4 12574241 10.1128/JCM.41.2.531-534. 2003 (Pubitemid 36184156)
27. D Lyras JR O'Connor PM Howarth, et al. 2009 Toxin B is essential for virulence of Clostridium difficile Nature 458 1176 9 19252482 10.1038/nature07822 1:CAS:528:DC%2BD1MXisVOrtLg%3D
28. Onderdonk AB, Garrett WS. Gas gangrene and other Clostridium-associated diseases. In: Mandel et al. editors. Mandel, Douglas, and Bennett's principles and practice of infectious diseases, 7th edition. Elsevier; 2009: Chapter 246.
29. MJT Crobach OM Dekkers MH Wilcox EJ Kuijper 2009 European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI) Clin Microbiol Infect 15 1053 66 19929972 10.1111/j.1469-0691.2009.03098.x 1:STN:280:DC%2BD1Mjns1Gntg%3D%3D In this review, a comprehensive analysis of all available data regarding C. difficile assays is performed with updated recommendations for testing
30. S Sharp LO Ruden JC Pohl, et al. 2010 Evaluation of the C.Diff Quick Chek Complete assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease J Clin Microbiol 48 2082 6 20375230 10.1128/JCM.00129-10
31. K Eastwood P Else A Charlett M Wilcox 2009 Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for Clostridium difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods J Clin Microbiol 47 3211 7 19710274 10.1128/JCM.01082-09 This recent article describes a side-by-side comparison of multiple assays for CDI including a newly developed PCR test
32. CW Knetsch D Bakker RF de Boer, et al. 2011 Comparison of Real-Time PCR techniques to cytotoxigenic culture methods for diagnosing Clostridium difficile infection J Clin Microbiol 49 1 227 31 20980562 10.1128/JCM.01743-10 1:CAS:528:DC%2BC3MXjtFSgur4%3D
33. RJ Van Den Berg N Vaessen T Endtz, et al. 2007 Evaluation of a real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study J Med Microbiol 56 36 42 17172514 10.1099/jmm.0.46680-0 (Pubitemid 46036272)
34. LR Peterson RU Manson SM Paule, et al. 2007 Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea Clin Infect Dis 45 1152 60 17918076 10.1086/522185 1:CAS:528:DC%2BD2sXht1ykt7jN (Pubitemid 47580313)
35. J Ansari B Choo I Fernando 2010 Fatal Clostridium difficile infection associated with vinorelbine chemotherapy:case report and literature review J Infect Chemother 16 210 2 20198401 10.1007/s10156-010-0041-0
36. DG Teasley DN Gerding MM Olson, et al. 1983 Prospective randomized trial of metronidazole versus vancomycin for the treatment of Clostridium difficile-associated diarrhea and colitis Lancet 2 1043 6 6138597 10.1016/S0140-6736(83)91036-X 1:STN:280:DyaL2c%2FjvVCrug%3D%3D (Pubitemid 14235361)
37. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. 1996;22:813-18.
38. FA Zar SR Bakkanagari KM Moorthi, et al. 2007 A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity Clin Infect Dis 45 302 7 17599306 10.1086/519265 1:CAS:528:DC%2BD2sXptVKnur8%3D This study classified CDAD cases by severity using six clinical variables and demonstrated that vancomycin was superior to metronidazole for the treatment of severe CDAD (Pubitemid 47101025)
39. DM Musher S Aslam N Logan, et al. 2005 Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole Clin Infect Dis 40 1586 90 15889354 10.1086/430311 1:CAS:528:DC%2BD2MXltlCltLo%3D (Pubitemid 40720807)
40. T Pelaez L Alcala R Alonso, et al. 2002 Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin Antimicrob Agents Chemother 46 1647 60 12019070 10.1128/AAC.46.6.1647-1650.2002 1:CAS:528:DC%2BD38XktFCnu7s%3D (Pubitemid 34535177)
41. R Alonso S Gros T Pelaez, et al. 2001 Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile-associated diarrhoea J Hosp Infect 48 86 92 11428873 10.1053/jhin.2001.0943 1:STN:280:DC%2BD3Mznt1WqtQ%3D%3D (Pubitemid 32700706)
42. J Pepin N Saheb MA Coulombe, et al. 2005 Emergence of flouroquinolones as the predominant risk factor for Clostridium-difficile associated diarrhea Clin Infect Dis 41 1254 60 16206099 10.1086/496986 1:CAS:528:DC%2BD2MXht1WitrzK (Pubitemid 41532667)
43. S Johnson C Schriever M Galang, et al. 2007 Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin Clin Infect Dis 44 846 8 17304459 10.1086/511870 1:CAS:528:DC%2BD2sXjs1Ggtr4%3D (Pubitemid 46365312)
44. I Lowy DC Molrine BA Leav, et al. 2010 Treatment with monoclonal antibodies against Clostridium difficile toxins N Engl J Med 362 3 197 205 20089970 10.1056/NEJMoa0907635 1:CAS:528:DC%2BC3cXosFShtw%3D%3D This is the first randomized controlled trial of intravenous immunoglobulin therapy in the treatment of CDI. Results from this trial suggest that IVIG therapy may decrease the risk of CDI recurrence
45. MH Floch 2010 Fecal biotherapy, fecal transplant and the microbiome J Clin Gastroenterol 44 8 529 30 20601895 10.1097/MCG.0b013e3181e1d6e2
46. MJ Grehan TJ Borody SM Leis, et al. 2010 Durable alteration of the colonic microbiota by the administration of donor fecal flora J Clin Gastroenterol 44 8 551 61 20716985 10.1097/MCG.0b013e3181e5d06b Although multiple previous studies have demonstrated the effectiveness of fecal biotherapy in prevention of CDI recurrence by recolonization of the colonic lumen, this study demonstrates that the fecal flora of individuals can be reliably manipulated using donor feces
47. R Eddi MN Malik R Shakov, et al. 2010 Chronic kidney disease as a risk factor for Clostridium difficile infection Nephrology 15 4 471 5 20609100 10.1111/j.1440-1797.2009.01274.x
48. R Das P Feuerstadt LJ Brandt 2010 Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease Am J Gastro 105 2040 9 10.1038/ajg.2010.142 1:CAS:528:DC%2BC3cXhtFaitrfJ This is the first major study to demonstrate increased mortality associated with glucocorticoid administration in the setting of CDAD
49. ZF Gellad BD Alexander BC Liu, et al. 2007 Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients Transpl Infect Dis 9 276 80 17635835 10.1111/j.1399-3062.2007.00255.x 1:STN:280: DC%2BD2snmtVGmsw%3D%3D (Pubitemid 350059151)
50. D Bobak LM Arfons RJ Creger HM Lazarus 2008 Clostridium difficile-associated disease in human stem cell transplant recipients:coming epidemic or false alarm? Bone Marrow Transplant 42 705 13 18836490 10.1038/bmt.2008.317 1:STN:280:DC%2BD1cjpsFOjug%3D%3D In this review, the current heterogeneous data regarding CDI in BMT are compiled and analyzed